Repurposing of prochlorperazine for use against dengue virus infection

Journal of Infectious Diseases

Volumn 211, Issue 3, 2015, Pages 394-404

  Simanjuntak, Yogy ^a,b   Liang, Jian Jong ^b   Lee, Yi Ling ^b   Lin, Yi Ling ^a,b,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

clathrin mediated endocytosis; dengue virus; dopamine D2 receptor; drug repurposing; prochlorperazine

Indexed keywords

CLATHRIN; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; PROCHLORPERAZINE DIMESYLATE; PROCHLORPERAZINE MALEATE; STAT1 PROTEIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; PROCHLORPERAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 2; DISEASE MODEL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENCY; DRUG REPOSITIONING; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; LOW DRUG DOSE; MORTALITY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN DEFICIENCY; VIROGENESIS; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; CELL LINE; DENGUE VIRUS; DRUG EFFECTS; PROCEDURES;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DENGUE; DENGUE VIRUS; DRUG REPOSITIONING; HUMANS; MICE; PROCHLORPERAZINE; VIRUS REPLICATION;

EID: 84922513708     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu377     Document Type: Article

References (49)

1. Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010; 8:S7-16.
2. Simmons CP, Farrar JJ, Nguyen vV, Wills B. Dengue. N Engl J Med 2012; 366:1423-32.
3. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7.
4. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Micro-biol 2002; 10:100-3.
5. Gubler DJ. The economic burden of dengue. Am J Trop Med Hyg 2012; 86:743-4.
6. Clyde K, Kyle JL, Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 2006; 80:11418-31.
7. Rodenhuis-Zybert IA, Wilschut J, Smit JM. Dengue virus life cycle: viral and host factors modulating infectivity. Cell Mol Life Sci 2010; 67:2773-86.
8. Smit JM, Moesker B, Rodenhuis-Zybert I, Wilschut J. Flavivirus cell entry and membrane fusion. Viruses 2011; 3:160-71.
9. Coller BA, Clements DE. Dengue vaccines: progress and challenges. Curr Opin Immunol 2011; 23:391-8.
10. Schmitz J, Roehrig J, Barrett A, Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011; 29:7276-84.
11. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67.
12. Noble CG, Shi PY. Structural biology of dengue virus enzymes: towards rational design of therapeutics. Antiviral Res 2012; 96:115-26.
13. Low JSY, Chen KC, Wu KX, Ng M-LM, Chu JJH. Antiviral activity of emetine dihydrochloride against dengue virus infection. J Antivir Anti-retrovir 2009; 1:62-71.
14. Whitby K, Pierson TC, Geiss B, et al. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol 2005; 79:8698-706.
15. Martinez-Gutierrez M, Castellanos JE, Gallego-Gomez JC. Statins reduce dengue virus production via decreased virion assembly. Intervirol-ogy 2011; 54:202-16.
16. Yin Z, Chen YL, Schul W, et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci USA 2009; 106:20435-9.
17. Rathore AP, Paradkar PN, Watanabe S, et al. Celgosivir treatment mis-folds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res 2011; 92:453-60.
18. Watanabe S, Rathore AP, Sung C, et al. Dose-and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res 2012; 96:32-5.
19. Whitehorn J, Farrar J. Dengue. Br Med J 2010; 95:161-73.
20. Ramos MM, Tomashek KM, Arguello DF, et al. Early clinical features of dengue infection in Puerto Rico. Trans R Soc Trop Med Hyg 2009; 103:878-84.
21. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63:182-217.
22. Gastaminza P, Whitten-Bauer C, Chisari FV. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc Natl Acad Sci USA 2010; 107:291-6.
23. Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 2012; 30:4301-6.
24. Leyssen P, De Clercq E, Neyts J. Perspectives for the treatment of infections with flaviviridae. Clin Microbiol Rev 2000; 13:67-82.
25. Wang LH, Rothberg KG, Anderson RGW. Miss-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol 1993; 123:1107-17.
26. van der Schaar HM, Rust MJ, Chen C, et al. Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. PLoS Pathog 2008; 4:e1000244.
27. Blanchard E, Belouzard S, Goueslain L, et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 2006; 80: 6964-72.
28. Chu JJ, Ng ML. Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. J Virol 2004; 78:10543-55.
29. Alexander B, Browse DJ, Reading SJ, Benjamin IS. A simple and accurate mathematical method for calculation of the EC50. J Pharmacol Toxicol 1999; 41:55-8.
30. Chen ST, Lin YL, Huang MT, et al. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 2008; 453:672-6.
31. Li PC, Liao MY, Cheng PC, et al. Development of a humanized antibody with high therapeutic potential against dengue virus type 2. PLoS Negl Trop Dis 2012; 6:e1636.
32. McKenna F, McLaughlin PJ, Lewis BJ, et al. Dopamine receptor expression on human T-and B-lymphocytes, monocytes, neutrophils, eosino-phils and NK cells: a flow cytometric study. J Neuroimmunol 2002; 132:34-40.
33. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 1998; 78:189-225.
34. Matsumoto L, Takuma H, Tamaoka A, et al. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One 2010; 5:e15522.
35. Yang-Hong P, Jing-Ming Z, Nai-Kang Z, Shan W. Expression of dopa-mine receptor D2 in pulmonary carcinoma cells and effects of dopa-mine on the cell apoptosis. J South Med Univ 2011; 6:975-8.
36. Watanabe Y, Kato A, Sawara K, et al. Selective alterations of brain dop-amine D(2) receptor binding in cirrhotic patients: results of a (11)C-N-methylspiperone PET study. Metab Brain Dis 2008; 23:265-74.
37. Skinbjerg M, Seneca N, Liow JS, et al. Dopamine beta-hydroxylase-de-ficient mice have normal densities of D(2) dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioli-gand binding. Synapse 2010; 64:699-703.
38. Maggos CE, Tsukada H, Kakiuchi T, et al. Sustained withdrawal allows normalization of in vivo [11C]N-Methylspiperone dopamine D2 receptor binding after chronic bige cocaine: a positron emission tomography study in rats. Neuropsychopharmacol 1998; 19:146-53.
39. Lyon RA, Titeler M, Frost JJ, et al. 3-H-N-Methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotoninn receptors in cerebral cortex. J Neurosci 1986; 6:2941-9.
40. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996; 84:443-50.
41. Hamik A, Peroutka SJ. Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol 1989; 24:307-10.
42. Smith JL, Stein DA, Shum D, et al. Inhibition of dengue virus replication by a class of small molecule compounds that antagonize dopamine receptor 4 and downstream mitogen activated protein kinase signaling. J Virol 2014; 88: 5533-42.
43. Sigma. Prochlorperazine Dimaleate (Material safety data sheet). http://tws.tu.edu/webdocs/msds/Prochlorperazine.pdf. Accessed 21 July 2014.
44. Science Lab. Prochlorperazine Maleate (Material safety data sheet). http://www.sciencelab.com/msds.php?msdsId=9924717. Accessed 21 July 2014.
45. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22:659-61.
46. Fallon R, Fraser C, Moriarty K. Recommended management of nausea and vomiting. Prescriber 2007; 18:50-61.
47. Jones JM, Qin R, Bardia A, Linquist B, Wolf S, Loprinzi CL. Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Palliat Med 2011; 14:810-4.
48. Jellish WS, Owen K, Fluder E, Sawicki K, Sinacore J. Patient-controlled analgesia combined with either ondansetron or ondansetron plus prochlorperazine for control of pain and nausea and vomiting in patients undergoing abdominal surgery. J Clin Anesth 2008; 20: 594-600.
49. Lambert M, Conus P, Lambert T, McGorry PD. Pharmacotherapy of first-episode psychosis. Expert Opin Pharmacother 2003; 4:717-50.